Physician profile
Shaheda Akhtar
NPI 1689605503
$2,968.10
in general payments reported to CMS, 2019-2025
14 companies · $37.47 in 2025
The $37.47 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $205 · 2021: $148 · 2022: $694 · 2023: $754 · 2024: $304 · 2025: $37.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.73 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $387.24 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $327.37 | 2022-2024 | Lybalvi, Aristada |
| Allergan, INC. | $319.70 | 2019-2020 | |
| Tris Pharma INC | $243.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $239.13 | 2019-2022 | |
| Corium, LLC | $146.50 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $128.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $121.73 | 2020 | |
| Sunovion Pharmaceuticals INC. | $117.18 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $112.00 | 2024 | Ingrezza |
| Scilex Pharmaceuticals INC. | $65.23 | 2019 | |
| Emergent Biosolutions INC. | $20.34 | 2019 | |
| Pfizer INC. | $20.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaheda Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.